SENSEX
NIFTY 50
Hang Seng
Taiwan Weighted
MCX GOLD OCT 05
MCX SILVER SEP 04
USD/INR
EUR/INR80.0630

SENSEX
NIFTY 50
NIFTY MIDCAP 100
S&P BSE MIDCAP
Hang Seng
Taiwan Weighted
DAX
Nasdaq
MCX GOLD OCT 05
MCX SILVER SEP 04
MCX CRUDEOIL AUG 19
MCX NATURALGAS AUG 26
USD/INR
EUR/INR
GBP/INR
JPY/INR

This mid-cap pharma stock turned Rs 1,00,000 to Rs 3,17,000 in just four months

Global stocks on defensive as US-China tensions spook investors

Oil prices slip on uncertainty over US recovery, stimulus

Rupee ends marginally lower; appreciates by 0.24% for the week

Earnings

Dabur Q1 net profit falls 5.9% to Rs 341.8 crore; volumes decline 9.7%

Updated : July 31, 2020 10:21 AM IST

Dabur's domestic volume during Q1FY21 declined at 9.7 percent versus expectations of 14-15 percent decline.

The quarter saw our new products record sales of over Rs 100 crore.

Dabur India reported a net 5.9 percent fall in net profit at Rs 341.8 crore for the quarter ended June 2020 crore as against Rs 363.1 crore in the same period last year. The profit beat CNBC-TV18 analysts' poll estimates of Rs 330 crore.

Revenue during the quarter declined 12.9 percent to Rs 1,980 crore from Rs 2,273.3 crore, YoY. Revenue was higher than estimates of Rs 1,975 crore.

Dabur's domestic volume in Q1FY21 fell at 9.7 percent versus expectations of 14-15 percent decline.

EBITDA fell 8.9 percent to Rs 416.6 crore from Rs 457.6 crore while EBITDA margin improved by 93 bps to 21.04 percent from 20.1 percent, year on year.

"Despite a challenging April, the quarter saw a nearly 7-fold growth in demand for Dabur Chyawanprash and an over 60% surge in demand for Dabur Honey. Dabur has significantly ramped up capacity with production now at near-normal levels and the business poised to deliver growth for the rest of the year," said Mohit Malhotra, Chief Executive Officer, Dabur India.

Dabur Chyawanprash reported a growth of over 694 percent during the quarter, while Dabur Honitus grew by over 80 percent while Dabur Honey ended Q1 2020-21 with a growth of over 60 percent.

The quarter saw Dabur introduce a record number of new products and variants anchored on the consumer need for Health, Immunity and Hygiene.

The quarter saw our new products record sales of over Rs 100 crore.

The OTC Healthcare Business ended the quarter with a 34 percent growth while the Ayurvedic Ethicals business was up 11 percent. The Toothpaste Business, on the back of continued demand for our flagship Dabur Red Paste, ended the quarter with a nearly 3 percent growth, it added.

You May Also Like

Coronavirus news latest updates: 1.45 lakh cases in Delhi, Andhra Pradesh tally spirals to 2.27 lakh with 10,820 new cases

Coronavirus news latest updates: 1.45 lakh cases in Delhi, Andhra Pradesh tally spirals to 2.27 lakh with 10,820 new cases

Exclusive: Homegrown short video app Chingari raises seed funding of $1.3 million

Exclusive: Homegrown short video app Chingari raises seed funding of $1.3 million

Jubilant Life Sciences presents 1,000 vials of remdesivir to UP CM Yogi Adityanath

Jubilant Life Sciences presents 1,000 vials of remdesivir to UP CM Yogi Adityanath

Trending on CNBC-TV18

Live TV

recommended for you